Why Oscar Health is on investors’ radar today

Oscar Health (OSCR) is attracting fresh attention after recent trading, with the stock last closing at US$22.23. Investors are weighing this price against the company’s recent returns and fundamentals.

Recent trading has been choppy, with the share price down 0.45% over the last day and 1.81% over the week. Even so, the 30 day share price return of 20.23% and year to date share price return of 48.5% sit alongside a 1 year total shareholder return of 55.89% and a 3 year total shareholder return of 167.83%, suggesting momentum has been building over a longer horizon even with some short term cooling.

If Oscar Health has caught your attention, this can be a good moment to see what else is moving in healthcare technology by scanning 39 healthcare AI stocks

With Oscar Health now at US$22.23 and trading slightly above the average analyst price target of US$21.20, the question is whether the recent run leaves upside on the table or if the market is already pricing in future growth.

Most Popular Narrative: 44.4% Overvalued

At a last close of $22.23 versus a narrative fair value of $15.40, the current price sits well above what the most followed model suggests, bringing the underlying growth and margin assumptions into sharp focus.

Recent market-wide increases in morbidity within the individual ACA market highlight Oscar Health's vulnerability to dynamic risk pools, heightening uncertainty in claims costs and putting pressure on the company's ability to maintain or grow net margins and future earnings, even with planned repricing actions.

Want to understand why this narrative still sees earnings power building despite those pressures? Revenue expansion, margin repair and a re rated profit multiple sit at the core. Curious how those ingredients combine to support that $15.40 fair value against today’s share price premium?

Result: Fair Value of $15.40 (OVERVALUED)

However, analysts also flag that higher claims costs in the ACA market, along with tighter data privacy rules, could pressure margins and challenge the current earnings narrative.

Another View on Oscar Health’s Valuation

The narrative fair value of $15.40 suggests Oscar Health looks overvalued at $22.23, but the market is telling a different story. On a price-to-sales (P/S) ratio of about 0.5x, the stock trades well below the US Insurance industry at 1x, the peer average at 1.2x, and even the fair ratio of 0.7x. This points to a clear valuation gap that could either close through price moves or through changing fundamentals. Which side of that gap do you think will move first?

For a closer look at how these numbers stack up against similar companies, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of overvaluation concerns and potential upside rewards means sentiment is far from settled. Investors may wish to move quickly, review the numbers, and weigh both the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If Oscar Health has sharpened your focus, do not stop here. Widen your search now or you may miss cleaner balance sheets, steadier returns, and fresh opportunities.

• Target sturdier portfolios by zeroing in on companies with stronger finances using the solid balance sheet and fundamentals stocks screener (46 results).
• Spot potential value early by scanning the screener containing 22 high quality undiscovered gems before they attract wider market attention.
• Dial back portfolio volatility by focusing on companies appearing in the 64 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.